Alpha-1 Antitrypsin (A1AT)

A quick unit note clears up most of the confusion across reports. Many US labs print alpha-1 antitrypsin in mg/dL while others use g/L, and a g/L value is roughly a hundred times smaller than the mg/dL figure for the same result, so 1.5 g/L sits around 150 mg/dL. The threshold most often quoted for the lungs, about 11 µmol/L, also maps to different mg/dL values depending on the assay the lab runs, which is part of why a single memorized cutoff is unreliable. Read your result against the range printed on your own report.

A low level is the result that matters, because it points toward an inherited deficiency rather than something temporary. The gene comes in versions, and which two you carry decides how much working protein you make. MedlinePlus Genetics lays out the common ones: the M allele makes normal protein, so two M alleles (the usual genotype) produce a normal supply. Two Z alleles carry a high risk of both lung and liver disease. An S paired with a Z raises lung-disease risk, especially in smokers. A single Z paired with an M, the MZ carrier state, carries a slightly increased risk of impaired lung or liver function.

The mechanism behind the most severe form is worth understanding, because it explains why one defect harms two organs. The PMC liver-disease review describes the Z-type protein as misfolded: it polymerizes and gets trapped inside the liver cell instead of being secreted into the blood. That single fault produces two separate injuries. The lungs are left short of their protection, a loss of function that lets neutrophil elastase chip away at lung tissue. The liver, meanwhile, accumulates the stuck protein, a gain-of-function injury where the backlog itself damages the cells holding it.

The conditions that follow have a recognizable shape. The NHLBI notes that the lung side typically surfaces between ages 20 and 50 as emphysema or COPD, which is why "COPD at a young age and never smoked" is the line that so often leads people to this test. The liver side can appear at any age, from jaundice in infancy to unexplained liver enzyme elevation in an adult, where markers like ALT and its companion AST drift up without an obvious cause.

A high level on its own is rarely the headline, because the protein climbs with so many ordinary states. The same acute-phase behavior that masks a deficiency also produces transient highs during infection, inflammation, and pregnancy. Read in isolation a high value usually says only that the body is mounting an inflammatory response somewhere, which is why clinicians lean on markers built for that job rather than reading alpha-1 antitrypsin as an inflammation gauge. The reason this protein earns its own page is the low end and the inherited story behind it.

This protein sits on the liver panel for a reason: the liver is both its factory and, in deficiency, one of its victims. When the level is low and the question turns to liver involvement, the enzymes do the talking. The comparison between ALT and AST explains how those two move together and apart, and a rise in GGT adds detail about the bile side of the picture. The protein-balance markers matter too, since alpha-1 antitrypsin is itself part of the globulin fraction: a shift in albumin against globulin is part of how a struggling liver shows itself. The guide to reading a liver panel walks through how these fit together.

The deeper point this marker drives home is about timing, not just genetics. A single level taken during an illness can mislead in either direction, which is exactly why one normal number settles nothing when family history or symptoms point toward alpha-1. The protein is most telling when read against its companions, the liver enzymes and the albumin-to-globulin balance, rather than judged as a number standing alone.